$5.87—Stale · unknown old
NASDAQ • Last print unknown agoAbout this data
$5.87—Stale · unknown old
SBTX News
About
Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically administered to patients. Silverback Therapeutics serves customers worldwide.
Leadership (7)
Peter A. ThompsonCo-Founder & Chairman of Directors
Jen MoreDirector of HR
Sue HamkeSenior Vice President of Clinical Operations
Jeffrey C. PepeInterim Chief Executive Officer, Gen. Counsel & Corporation Sec.
Miguel ArcinasVice President of Corporation Devel. & Investor Relations
Dario GobunquinSenior Director of Accounting & Controller
Russ HawkinsonSenior Vice President of Fin., Interim Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers